Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.43 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.43 |
| ▸ | AHCY | P23526 | 2/20 | 0.41 |
| ▸ | ADA | P00813 | 1/20 | 0.36 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.35 |
| ▸ | AMD1 | P17707 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20010089 | 0.90 | ADORA2A (0.47) | ADORA2AADORA2BDNMT1DNMT3BAHCY | |
| SCHEMBL20010217 | 0.89 | ADORA2A (0.46) | ADORA2AADORA2BDNMT1DNMT3BAHCY | |
| SCHEMBL20010221 | 0.89 | ADORA2A (0.46) | ADORA2AADORA2BDNMT1DNMT3BAHCY | |
| SCHEMBL20010146 | 0.87 | ADORA2A (0.45) | ADORA2AADORA2BDNMT1DNMT3BAHCY | |
| SCHEMBL14946123 | 0.81 | ADORA2A (0.48) | ADORA2AADORA2BDNMT1DNMT3BAHCY | |
| SCHEMBL18852383 | 0.81 | ADORA2A (0.48) | ADORA2AADORA2BDNMT1DNMT3BAHCY | |
| SCHEMBL15868515 | 0.81 | ADORA2A (0.48) | ADORA2AADORA2BDNMT1DNMT3BAHCY | |
| SCHEMBL14928885 | 0.81 | ADORA2A (0.48) | ADORA2AADORA2BDNMT1DNMT3BAHCY | |
| SCHEMBL20009992 | 0.79 | ADORA2A (0.43) | ADORA2AADORA2BDNMT1DNMT3BAHCY | |
| SCHEMBL20010088 | 0.79 | ADORA2A (0.43) | ADORA2AADORA2BDNMT1DNMT3BAHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNATX, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | ADORA2A 3329/4885ADORA2B 3118/4885DNMT1 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.